http://orcid.org/0000-0002-8642-305X
References
- Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069.
- Kubota Y, McAdams-DeMarco M, Folsom AR. Serum uric acid, gout, and venous thromboembolism: the atherosclerosis risk in communities study. Thromb Res. 2016;144:144–148.
- Chiu CC, Chen YT, Hsu CY, et al. Association between previous history of gout attack and risk of deep vein thrombosis – a nationwide population-based cohort study. Sci Rep. 2016;6(1):26541.
- Kuwabara M. Hyperuricemia, cardiovascular disease, and hypertension. Pulse (Basel). 2016; 3(3–4):242–252.
- Yu T, Weinreb N, Wittman R, et al. Secondary gout associated with chronic myeloproliferative disorders. Semin Arthritis Rheum. 1976;5(3):247–256.
- Denman M, Szur L, Ansell BM. Hyperuricaemia in polycythaemia vera. Ann Rheum Dis. 1966; 25(4):340–344.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
- Haider M, Gangat N, Lasho T, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016;91(4):390–394.
- Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470.
- Desideri G, Castaldo G, Lombardi A, et al. Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci. 2014;18(9):1295–1306.
- Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390.
- Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405.
- Liu M, Li XC, Lu L, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2014;18(19):2918–2926.
- Christensen AS, Møller JB, Hasselbalch HC. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38(4):490–495.
- Said SM, Leung N, Sethi S, et al. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011;80(7):753–759.